β-Lactamases: Mechanisms of Action and Detection Applications—A Technical Guide

β-Lactamases are a family of enzymes that hydrolyze the β-lactam ring and inactivate β-lactam antibacterial agents, constituting a major molecular basis for acquired bacterial resistance. β-Lactam antibiotics primarily target penicillin-binding proteins (PBPs) and disrupt peptidoglycan synthesis, leading to cell-wall defects and bacterial death. In contrast, β-lactamases directly destroy the drug’s core ring structure, reducing effective PBP inhibition and yielding resistant phenotypes. β-Lactamases are diverse, spanning serine-dependent β-lactamases and metallo-β-lactamases (MBLs) that rely on metal ions for catalysis. Differences in substrate spectrum, inhibitor susceptibility, genetic carriage and dissemination characteristics determine clinical therapeutic choices, resistance surveillance strategies and infection-control pathways. In research and testing settings, β-lactamases are also central targets for mechanism studies, inhibitor screening, diagnostic method development and resistance-risk assessment.

Keywords: β-lactamase; penicillin-binding protein (PBP); ESBL; AmpC; carbapenemase; metallo-β-lactamase (MBL); inhibitor; resistance surveillance

I. Overview and Research Background

1.1 Definition and Significance in Antimicrobial Resistance

β-Lactamases (β-lactamase) hydrolyze the β-lactam ring and inactivate drugs, thereby weakening the antibacterial activity of penicillins, cephalosporins, monobactams and carbapenems. Their expression level, cellular localization (typically periplasmic in Gram-negative bacteria) and synergy with reduced outer-membrane permeability and enhanced efflux can markedly increase tolerance to β-lactam agents and raise the risk of treatment failure.

1.2 Application Positioning

β-Lactamase-related research and applications are commonly organized along three main lines:

(1) Resistance mechanism elucidation and epidemiological surveillance.

(2) Phenotypic and genotypic diagnostics in clinical microbiology laboratories.

(3) Drug development and inhibitor evaluation, including β-lactamase inhibitors and combination strategies with new β-lactam agents.

II. Mechanism of Action and Target Basis of β-Lactam Antibiotics

2.1 Shared Mode of Action of β-Lactam Antibacterials

(1) PBPs as the primary targets

① Many β-lactam agents inhibit enzymes involved in peptidoglycan synthesis; the key targets are membrane-associated penicillin-binding proteins (PBPs).

② PBPs catalyze peptidoglycan crosslinking and maturation. Drug binding blocks critical steps and compromises cell-wall integrity.

(2) Cellular consequences of bactericidal action

① Inhibited cell-wall synthesis leads to structural defects; under osmotic stress, bacteria undergo morphological changes and tend toward lysis and death.

② In some organisms, β-lactams can induce or enhance autolysin-associated activities, accelerating wall disruption. Mutants lacking autolytic functions may exhibit increased resistance or tolerance.

(3) Selectivity toward bacteria versus the host

① Mammalian cells lack a peptidoglycan cell wall, so β-lactams have no equivalent target structure in host cells, resulting in relative selectivity for bacteria.

2.2 Functional Division of PBPs and Representative Examples

(1) Species differences and taxonomic consistency of PBP repertoires

① The number, molecular mass and affinity profiles of PBPs vary by species, but closely related bacteria often share similar PBP repertoires and functional allocation.

(2) Functional partitioning in Escherichia coli as an example

① Multiple PBPs are detectable in E. coli. PBP1A and PBP1B are associated with cell elongation; some penicillins and cephalosporins show relatively high affinity for these targets, and inhibition may impede growth and elongation with a tendency toward lysis.

② PBP2 contributes to shape maintenance; certain drugs bind preferentially and can cause characteristic morphological changes, sometimes with delayed lysis under specific conditions.

③ PBP3 is involved in division and septum formation; many β-lactams bind PBP1 and/or PBP3, leading to filamentation or spheroplast formation and eventual cell death.

④ Some low-molecular-weight PBPs are associated with carboxypeptidase-like activities and are not strictly essential for survival; binding to these targets often has a limited impact on viability.

The key implication is that bactericidal outcomes depend strongly on the drug–PBP binding spectrum, whereas β-lactamases confer resistance by destroying drug structure and reducing effective binding.

III. Mechanisms of β-Lactamases and Structure–Function Features

3.1 Two Major Catalytic Frameworks

(1) Serine β-lactamases

① A catalytic serine residue in the active site typically mediates β-lactam ring opening via an acylation and deacylation cycle.

(2) Metallo-β-lactamases (MBLs)

① Catalysis depends on divalent metal ions—commonly Zn2+—to activate water and facilitate nucleophilic attack through metal coordination, resulting in ring opening.

② Activity is sensitive to the metal-ion environment; chelators can markedly reduce activity, and most MBLs are not inhibited by classic serine β-lactamase inhibitors.

3.2 Substrate Spectrum and Inhibitor Susceptibility

Different β-lactamases vary substantially in their hydrolytic activity against β-lactam subclasses. Inhibitor susceptibility also differs: some serine β-lactamases are strongly or moderately inhibited by classic inhibitors, whereas MBLs are generally not effectively suppressed by them. In experimental and diagnostic settings, avoid inferring enzyme type from a single drug or inhibitor result; multi-substrate, multi-control interpretation is recommended.

IV. Classification Systems and Representative Types

4.1 Ambler Molecular Classification (by Structure and Catalytic Center)

β-Lactamases are commonly classified into Ambler classes A, B, C and D:

(1) Class A: serine β-lactamases, including many ESBLs and some carbapenemases

(2) Class B: MBLs, metal-dependent and often closely associated with carbapenem resistance

(3) Class C: AmpC-type serine β-lactamases, encoded chromosomally or carried on plasmids

(4) Class D: OXA-type serine β-lactamases, some members of which have carbapenemase activity

4.2 Functional Classification (by Substrate Spectrum and Clinical Phenotype)

(1) ESBLs

① ESBLs can hydrolyze extended-spectrum cephalosporins and monobactams; inhibitor responses depend on enzyme type, expression level and host background.

(2) AmpC

① AmpC enzymes hydrolyze multiple cephalosporins and are often influenced by inducible expression or derepression mutations affecting regulation.

(3) Carbapenemases

① Carbapenemases hydrolyze carbapenems and include both serine and metallo enzyme families. They are high-risk resistance indicators.

(4) Composite mechanisms

① β-Lactamases may act together with porin loss and efflux enhancement to yield complex resistance profiles, requiring integrated interpretation with the organism background.

V. Distribution and Dissemination Features of Metallo-β-Lactamases

5.1 Early Discovery and Chromosomal Distribution

(1) Early reports and representative organisms

① Early MBLs were reported in Bacillus cereus, showing zinc-dependent properties.

② In the early 1980s, a zinc-dependent penicillinase (L1-type) was identified in Stenotrophomonas maltophilia; MBLs with carbapenem (e.g., imipenem) hydrolytic activity were later identified in Aeromonas hydrophila, Bacteroides fragilis and other organisms.

(2) Genetic characteristics and clinical frequency

① These early enzymes were predominantly chromosomally encoded.

② In clinical isolates, aside from S. maltophilia where MBLs are comparatively more common, MBL carriage in other organisms is usually infrequent and sporadic in many regions. Actual frequency depends on region, specimen source and surveillance intensity; local data should be used for positioning.

5.2 Emergence and Spread of Plasmid-Mediated MBLs

(1) Key milestones of transferable MBLs

① In the early 1990s, plasmid-mediated MBLs were discovered in Pseudomonas aeruginosa, followed by transferable MBL types in B. fragilis, indicating the potential for dissemination via mobile genetic elements.

(2) Epidemic spread and host-range expansion

① Subsequently, increasing numbers of transferable MBLs have been reported across important clinical pathogens including P. aeruginosa, Acinetobacter spp. and Enterobacterales.

② Geographic distribution is no longer restricted to a single country or region, showing cross-regional transmission. Because local epidemic types and timelines differ, interpretation should be aligned with authoritative surveillance reports for the target region.

VI. Methods for Detection and Identification

6.1 Phenotypic Testing

(1) Antimicrobial susceptibility testing (AST) and interpretation framework

① MIC-based methods or diffusion assays are used to construct resistance profiles and provide preliminary evidence for β-lactamase-related mechanisms.

② Do not equate reduced susceptibility to a single agent with a specific enzyme type; interpret in the context of organism background and intrinsic mechanisms.

(2) Inhibitor synergy tests

① Sensitivity changes in the presence of a specific inhibitor can support inference of enzyme category.

② For MBL-related mechanisms, metal chelators can be used as functional indicators; include chelator-only controls to exclude non-specific growth effects.

(3) Rapid screening assays

① Colorimetric or spectrometric changes driven by substrate hydrolysis can be used for rapid screening and risk stratification.

② Include positive and negative controls and define time thresholds, with a confirmation strategy to reduce false classification.

6.2 Genotypic Testing

(1) PCR and sequencing

① Amplification and sequencing of common resistance genes can confirm enzyme type assignment and support typing analyses.

② Gene presence does not necessarily imply high expression; interpret alongside phenotype.

(2) Whole-genome sequencing (WGS)

① WGS enables simultaneous profiling of resistance genes, mobile elements and clonal transmission signals, supporting source tracing and epidemiological investigations.

② Annotation should be interpreted in view of database versions and threshold strategies to avoid mis-annotation and over-inference.

6.3 In Vitro Enzymology and Inhibitor Evaluation

(1) Substrate hydrolysis and kinetic analysis

① Hydrolysis rates and inhibition curves can be used to quantify enzyme activity and inhibitory potency.

② For MBL assays, strictly control metal-ion conditions and buffer composition to ensure comparability.

(2) Inhibitor screening and validation

① IC50 and related metrics can be used for initial screening, followed by cell-based validation such as MIC shifts or susceptibility restoration assays.

VII. Representative Application Scenarios

7.1 Clinical and Public-Health Resistance Surveillance

(1) Infection control and outbreak tracing

① Monitoring carbapenemases and MBL-associated mechanisms supports identification of transmission risk and informs control measures.

(2) Regional resistance profile surveillance

① Provides data support for antimicrobial stewardship and therapeutic optimization.

7.2 Drug Development and Inhibitor Screening

(1) Development of β-lactamase inhibitors

① Establish in vitro and cellular evaluation chains for different structural families, focusing on coverage breadth and resistance-mutation risk.

(2) Evaluation of new β-lactam agents

① Systematically assess drug stability and activity retention across different β-lactamase backgrounds.

7.3 Research and Method Development

(1) Construction of resistance models

① Heterologous expression of specific β-lactamases can generate model strains for mechanistic studies and method validation.

② Control expression level and host background to avoid directly extrapolating model results to complex clinical isolates.

(2) Reporter and screening systems

① β-Lactamase marker systems are widely used in molecular cloning, but biosafety and resistance-gene management considerations require compliance with institutional policies.

VIII. Quality Control and Troubleshooting

8.1 Key Design Elements for Testing Systems

(1) Control design

① Positive controls, negative controls and inhibitor controls are all essential.

② For MBL detection, add metal-ion condition controls and chelator-only controls.

(2) Thresholds and confirmation strategy

① Define interpretation thresholds aligned with the validated method and implement confirmation pathways to avoid misclassification from single-point results.

8.2 Common Issues and Diagnostic Pathways

(1) Phenotype–genotype discordance

① May relate to expression levels, induction conditions, gene mutations or composite resistance mechanisms.

② Recheck culture conditions and workflow, and apply orthogonal methods for cross-validation.

(2) Variable inhibitor synergy results

① May relate to inhibitor concentration, ionic environment or non-specific growth effects.

② Optimize conditions and strengthen the control set.

(3) Misclassification in rapid screening

① May be driven by matrix interference, time-threshold setting or low expression.

② Introduce time-course readouts and confirmatory testing.

IX. Aladdin-Related Products

Catalog No.	Product Name	Grade and Purity
L140816	β-lactamase	EnzymoPure™, lyophilized powder
L140135	β-lactamase	EnzymoPure™, ＞3,000,000 units/1ML
C405482	Cephalosporinase from Bacillus	EnzymoPure™, ≥5 million units/ml, 1ml/piece
rp216610	β-Lactamase Ⅳ	EnzymoPure™, BioReagent, sterile, 5000KU/bottle
M1508747	Metallo-β-lactamase	Bioactive, Recombinant, ActiBioPure™, High Performance, EnzymoPure™, sterile, expressed in E.coli;≥2M units/EA
P1508160	Penicillinase	Bioactive, Recombinant, ActiBioPure™, High Performance, EnzymoPure™, sterile, expressed in E.coli;≥10 M units/mL

β-Lactamases confer resistance by hydrolyzing the β-lactam ring and thereby reducing effective inhibition of PBPs. From early chromosomally encoded, relatively localized MBL distributions, the landscape has expanded to mobile genetic element–mediated spread and broader host ranges, substantially elevating public-health risk. For research and diagnostic use, high-confidence conclusions require an integrated framework combining structural classification with functional phenotypes, rigorous control design, standardized interpretation criteria and multi-method confirmation. Results should be interpreted together with organism background and regional epidemiology to support decision-making and reproducible research.

Aladdin: https://www.aladdinsci.com/